MarketWatchCenter·
Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
Read at MarketWatch →
Markets · 1 sources covering this
Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/e604ca4c6c3bcc0ce03b415df6cf0b646eacfae1" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars"></iframe>